文献速递中医内科针灸推拿中医康复

电针治疗卒中后抑郁的疗效与安全性:随机对照试验

Efficacy and safety of electroacupuncture for post-stroke depression: a randomized controlled trial.
PubMed 文献 · Acupunct Med · 2022-03-02

本单中心、单盲、平行组随机对照试验纳入65例卒中后抑郁患者,随机分为电针组与假电针组,取穴百会、四神聪、三阴交、太冲、肝俞,每周3次共4周。结果显示电针组HRSD、SDS、NIHSS、BI及中医郁证量表评分均显著改善,电针组2例局部血肿,假电针组无不良事件。

要点

  • 电针可改善卒中后抑郁患者的抑郁症状,第2、4、8周HRSD评分均显著优于假电针。
  • 电针同时改善神经功能缺损与日常生活活动能力,SDS、NIHSS、BI评分均显著改善。
  • 电针组出现2例局部血肿,假电针组无不良事件,安全性总体可接受。

核心结论

  • 电针可能是卒中后抑郁有效且安全的治疗方法,可减轻抑郁症状并改善神经功能与日常生活活动能力。

研究设计与样本

  • 单中心、单盲、平行组随机对照试验,共纳入65例卒中后抑郁患者,随机分为电针组与假电针组。
  • 两组均取百会、四神聪、三阴交、太冲、肝俞,电针组予电针,假电针组使用Park装置予假电针。
  • 治疗每周3次、共4周,主要结局为汉密尔顿抑郁量表(HRSD),次要结局包括SDS、NIHSS、BI及中医郁证量表。
  • 结局在基线、治疗第2周、第4周及随访第8周评估,安全性评估在4周治疗期间每次访视时进行。

主要发现

  • 电针组治疗前后HRSD、SDS、NIHSS、BI及中医量表评分均存在显著差异(均p < 0.001)。
  • 与假电针组相比,电针组HRSD评分在治疗第2周(F = 31.33,p < 0.001)、第4周(F = 35.58,p < 0.001)及第8周(F = 25.03,p < 0.001)均显著改善。
  • SDS、NIHSS及BI评分亦观察到显著改善。
  • 电针组2例出现局部血肿,假电针组未报告不良事件。

关键数值与推荐

  • 主要结局HRSD在治疗第2周F = 31.33、p < 0.001,第4周F = 35.58、p < 0.001,第8周F = 25.03、p < 0.001,均优于假电针组。
  • 电针组治疗前后HRSD、SDS、NIHSS、BI及中医量表评分均p < 0.001。
  • 电针组2例局部血肿,假电针组无不良事件。

临床怎么用

  • 对卒中后抑郁患者可考虑电针治疗,取百会、四神聪、三阴交、太冲、肝俞,每周3次、共4周。
  • 治疗期间需关注局部血肿等不良事件,本试验中电针组出现2例局部血肿。
  • 疗效评估可结合HRSD、SDS、NIHSS、BI及中医郁证量表,关注抑郁症状、神经功能与日常生活活动能力。

局限性

  • 本研究为单中心、单盲设计,样本量65例,结果外推需谨慎。
  • 假电针使用Park装置,对照设置可能影响盲法实施与结果解释。
  • 随访至第8周,缺乏更长期疗效与安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study is to evaluate the efficacy and safety of electroacupuncture (EA) treatment for post-stroke depression (PSD). METHODS: This study was a single-center, single-blinded, parallel-arm randomized controlled trial. In total, 65 patients with PSD were randomly allocated into EA and sham EA groups. Treatment was administered at GV20, Sishencong, SP6, LR3 and BL18 in both groups. The EA group received EA treatment, while the sham EA group received sham EA treatment using the Park device. Treatment was given three times a week for 4 weeks. The primary outcome was the Hamilton Rating Scale for Depression (HRSD). Secondary outcomes included the Zung Self-Rating Depression Scale (SDS), National Institutes of Health Stroke Scale (NIHSS), Barthel Daily Living Index (BI) and depression scale of traditional Chinese medicine (TCM). Primary and secondary outcomes were assessed at baseline, week 2 after treatment, week 4 after treatment and week 8 of follow-up. Safety assessment was conducted at each visit for 4 weeks of treatment. RESULTS: Significant differences in HRSD, SDS, NIHSS, BI and TCM scale scores were found in the EA group before and after acupuncture treatment (all p < 0.001). Compared with the sham EA group, HRSD scores improved significantly in the EA group at the end of week 2 (F = 31.33, p < 0.001), week 4 (F = 35.58, p < 0.001) and week 8 after treatment onset (F = 25.03, p < 0.001). Similarly, significant improvements were observed in SDS, NIHSS and BI scores. Two participants in the EA group suffered a local hematoma, while no adverse events were reported in the sham EA group. CONCLUSION: EA appears to be an efficacious and safe treatment for PSD. According to our results, EA may alleviate depressive symptoms, and improve neurological function and capabilities with respect to activities of daily living (ADLs). TRIAL REGISTRATION NUMBER: ChiCTR-IOR-17012610 (Chinese Clinical Trial Registry).

来源:Acupunct Med,查看原文。版权归原作者所有。

引用

  1. Cai W, Ma W, Li YJ, et al. Efficacy and safety of electroacupuncture for post-stroke depression: a randomized controlled trial. Acupunct Med. 2022. PMID: 35232229. doi:10.1177/09645284221077104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。